Akebia Therapeutics Is An Attractive Investment In 2018 [Seeking Alpha]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Seeking Alpha
Summary Headquartered in Cambridge, Massachusetts, Akebia Therapeutics ( AKBA ) has taken on the fast track route to transform from being a development-stage company to a leading fully integrated renal company with an anticipated pro-forma market capitalization of over $1.0 billion . The merger with commercial stage company, Keryx Pharmaceuticals, expected to be completed by end of 2018, has catapulted Akebia Therapeutics as a front line contended to investor dollars in the renal space. And things seem to have definitely picked up the pace, considering that Akebia Therapeutics and Keryx Pharmaceuticals have announced chairman for the combined company on November 15. In its third-quarter earnings , Akebia Therapeutics has managed to surpass both revenue and EPS estimates. The company's revenues of $53.17 million were higher than the consensus analyst estimate by $6.57 million, while GAAP loss per share of $0.46 was lower than the consensus estimate by $0.17. In the
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management [Seeking Alpha]Seeking Alpha
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?PR Newswire
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 4/16/24 - Form 8-K
- 3/28/24 - Form 8-K
- 3/15/24 - Form 8-K
- AKBA's page on the SEC website